Nasopharyngeal Cancer - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 194
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N6085FA6FE7EN
Leaflet:

Download PDF Leaflet

Nasopharyngeal Cancer - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Nasopharyngeal Cancer - Pipeline Review, H2 2016’, provides an overview of the Nasopharyngeal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer
  • The report reviews pipeline therapeutics for Nasopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nasopharyngeal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Nasopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Nasopharyngeal Cancer Overview
Therapeutics Development
Pipeline Products for Nasopharyngeal Cancer - Overview
Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis
Nasopharyngeal Cancer - Therapeutics under Development by Companies
Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes
Nasopharyngeal Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Nasopharyngeal Cancer - Products under Development by Companies
Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development
Advenchen Laboratories, LLC
Ambrx, Inc.
arGEN-X BV
Atara Biotherapeutics, Inc.
AVEO Pharmaceuticals, Inc.
Betta Pharmaceuticals Co. Ltd.
BioDiem Ltd
Biomics Biotechnologies Co., Ltd.
Celgene Corporation
Cell Medica Limited
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Lakewood-Amedex Inc
Merck & Co., Inc.
Merck KGaA
Molecular Partners AG
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pharmacyclics, Inc.
Sapvax
Tessa Therapeutics Pte Ltd
Theravectys SA
Nasopharyngeal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abexinostat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARGX-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atezolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azacitidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baltaleucel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Solid Tumor and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DC-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBV-nRNA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epstein-Barr virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ficlatuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2849330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAG-525 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MVA vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nimotuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDR-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5203280 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SV-638 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasopharyngeal Cancer - Dormant Projects
Nasopharyngeal Cancer - Discontinued Products
Nasopharyngeal Cancer - Product Development Milestones
Featured News & Press Releases
Jun 23, 2016: Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)
Jun 06, 2016: Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate
May 18, 2016: Atara Bio Announces Presentation of Clinical Data from EBV-CT Product Candidate at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 19, 2016: Atara Biotherapeutics Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor
Mar 16, 2016: Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research Annual Meeting
Sep 26, 2015: New Findings Show Anti-Tumor Activity of KEYTRUDA in Patients with Advanced Nasopharyngeal Carcinoma
Sep 10, 2015: U.S. FDA grants Fast Track Designation to Tessa Therapeutics’ TT10 EB-VST for the treatment of Head and Neck Cancers
Mar 27, 2015: U.S. FDA approves Tessa Therapeutic’s IND application to begin Phase III trial involving Adoptive T cell therapy on Nasopharyngeal Cancer
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Nasopharyngeal Cancer, H2 2016
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Investigation by Universities/Institutes, H2 2016
Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
Nasopharyngeal Cancer - Pipeline by Ambrx, Inc., H2 2016
Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H2 2016
Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016
Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
Nasopharyngeal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H2 2016
Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016
Nasopharyngeal Cancer - Pipeline by Celgene Corporation, H2 2016
Nasopharyngeal Cancer - Pipeline by Cell Medica Limited, H2 2016
Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Nasopharyngeal Cancer - Pipeline by Lakewood-Amedex Inc, H2 2016
Nasopharyngeal Cancer - Pipeline by Merck & Co., Inc., H2 2016
Nasopharyngeal Cancer - Pipeline by Merck KGaA, H2 2016
Nasopharyngeal Cancer - Pipeline by Molecular Partners AG, H2 2016
Nasopharyngeal Cancer - Pipeline by Novartis AG, H2 2016
Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Nasopharyngeal Cancer - Pipeline by Pharmacyclics, Inc., H2 2016
Nasopharyngeal Cancer - Pipeline by Sapvax, H2 2016
Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
Nasopharyngeal Cancer - Pipeline by Theravectys SA, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Nasopharyngeal Cancer - Dormant Projects, H2 2016
Nasopharyngeal Cancer - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Nasopharyngeal Cancer, H2 2016
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Advenchen Laboratories, LLC
Ambrx, Inc.
arGEN-X BV
Atara Biotherapeutics, Inc.
AVEO Pharmaceuticals, Inc.
Betta Pharmaceuticals Co. Ltd.
BioDiem Ltd
Biomics Biotechnologies Co., Ltd.
Celgene Corporation
Cell Medica Limited
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Lakewood-Amedex Inc
Merck & Co., Inc.
Merck KGaA
Molecular Partners AG
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pharmacyclics, Inc.
Sapvax
Tessa Therapeutics Pte Ltd
Theravectys SA
Skip to top


Uterine Cancer - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 50 pages
Oropharyngeal Cancer - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 136 pages
Gastric Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 962 pages
Esophageal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 448 pages
Thyroid Cancer - Pipeline Review, H1 2014 US$ 1,500.00 Jun, 2014 · 121 pages

Ask Your Question

Nasopharyngeal Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: